# Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma

> **NCT02429622** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 80 (actual)

## Conditions studied

- Esophageal Neoplasms

## Interventions

- **RADIATION:** IMRT simultaneous integrated boost
- **DRUG:** Paclitaxel
- **DRUG:** Nedaplatin
- **PROCEDURE:** Esophagectomy

## Key facts

- **NCT ID:** NCT02429622
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-10
- **Final completion:** 2016-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02429622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02429622, "Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02429622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*